NO20003968D0 - Farmasøytiske preparater - Google Patents

Farmasøytiske preparater

Info

Publication number
NO20003968D0
NO20003968D0 NO20003968A NO20003968A NO20003968D0 NO 20003968 D0 NO20003968 D0 NO 20003968D0 NO 20003968 A NO20003968 A NO 20003968A NO 20003968 A NO20003968 A NO 20003968A NO 20003968 D0 NO20003968 D0 NO 20003968D0
Authority
NO
Norway
Prior art keywords
pharmaceuticals
Prior art date
Application number
NO20003968A
Other languages
English (en)
Other versions
NO327675B1 (no
NO20003968L (no
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003968(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20003968D0 publication Critical patent/NO20003968D0/no
Publication of NO20003968L publication Critical patent/NO20003968L/no
Publication of NO327675B1 publication Critical patent/NO327675B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20003968A 2000-01-26 2000-08-04 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav. NO327675B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
NO20003968D0 true NO20003968D0 (no) 2000-08-04
NO20003968L NO20003968L (no) 2001-07-27
NO327675B1 NO327675B1 (no) 2009-09-07

Family

ID=9884259

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20003968A NO327675B1 (no) 2000-01-26 2000-08-04 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.
NO20003967A NO312434B1 (no) 2000-01-26 2000-08-04 Farmasöytiske preparater, samt anvendelse og fremgangsmåte for fremstilling derav
NO20071303A NO327554B1 (no) 2000-01-26 2007-03-09 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.
NO2010005C NO2010005I1 (no) 2000-01-26 2010-03-10 (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,SS)-3,5-dihydroksyhept-6-ensyre eller et farmasøytisk akseptabeltsalt og et tribasisk fosfatsalt hvor kationet er flerverdig

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20003967A NO312434B1 (no) 2000-01-26 2000-08-04 Farmasöytiske preparater, samt anvendelse og fremgangsmåte for fremstilling derav
NO20071303A NO327554B1 (no) 2000-01-26 2007-03-09 Farmasoytisk preparat inneholdende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre eller et farmasoytisk akseptabelt salt derav.
NO2010005C NO2010005I1 (no) 2000-01-26 2010-03-10 (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,SS)-3,5-dihydroksyhept-6-ensyre eller et farmasøytisk akseptabeltsalt og et tribasisk fosfatsalt hvor kationet er flerverdig

Country Status (48)

Country Link
US (2) US6548513B1 (no)
EP (6) EP2774609A1 (no)
JP (3) JP4800467B2 (no)
KR (3) KR100698333B1 (no)
CN (3) CN100528161C (no)
AP (2) AP1879A (no)
AR (3) AR023624A1 (no)
AT (3) AT412063B (no)
AU (5) AU2000264559A1 (no)
BE (2) BE1013413A3 (no)
BG (4) BG65234B1 (no)
BR (2) BR0003365A (no)
CA (3) CA2315141C (no)
CH (2) CH691347A5 (no)
CL (1) CL2007001807A1 (no)
CR (3) CR6568A (no)
CZ (3) CZ299105B6 (no)
DE (3) DE10038108A1 (no)
DK (3) DK178242B1 (no)
EE (3) EE04990B1 (no)
ES (2) ES2171123B1 (no)
FI (3) FI121365B (no)
FR (2) FR2795324B1 (no)
GB (3) GB0001621D0 (no)
HK (6) HK1036934A1 (no)
HR (3) HRP20020097B1 (no)
HU (2) HUP0003111A3 (no)
IL (4) IL150513A0 (no)
IS (3) IS1940B (no)
IT (2) ITTO20000779A1 (no)
ME (4) MEP33708A (no)
MY (2) MY122707A (no)
NL (2) NL1015858C2 (no)
NO (4) NO327675B1 (no)
NZ (2) NZ519774A (no)
PL (2) PL341855A1 (no)
PT (3) PT102504A (no)
RS (1) RS50201B (no)
RU (2) RU2264210C2 (no)
SE (2) SE523471C2 (no)
SI (1) SI1223918T1 (no)
SK (2) SK11792000A3 (no)
TR (3) TR200201888T2 (no)
TW (2) TW553749B (no)
UA (2) UA51853C2 (no)
WO (2) WO2001054668A1 (no)
YU (1) YU52902A (no)
ZA (2) ZA200003997B (no)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
EP1274401B2 (en) † 2000-04-10 2014-08-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
WO2004016262A1 (ja) * 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
EP3395338B1 (en) * 2003-09-12 2019-05-01 Amgen Inc. Rapid dissolution formulation of cinacalcet hcl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
DE602004032465D1 (de) * 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
ES2606149T3 (es) * 2004-05-04 2017-03-22 Innophos, Inc. Fosfato tricálcico directamente comprimible
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US7612203B2 (en) * 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
SI1944029T1 (sl) * 2005-10-31 2012-03-30 Kowa Co Farmacevtski pripravek ki ima odlično fotostabilnost
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
SI2024341T1 (sl) * 2006-05-03 2016-04-29 Msn Laboratories Private Limited Novi postopek za statine in njihove farmacevtsko sprejemljive soli
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
MX2010008466A (es) * 2008-01-30 2010-10-25 Lupin Ltd Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
JP2012502883A (ja) * 2008-06-13 2012-02-02 グラクソ グループ リミテッド 医薬製剤
EP2138165A1 (en) * 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2009156173A1 (en) * 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
BRPI0822782A2 (pt) * 2008-06-27 2015-09-29 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi composição farmacêutica que compreende rosuvastatina
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
AU2010281913A1 (en) 2009-08-13 2012-04-05 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
BR112015022103A2 (pt) * 2013-03-12 2017-07-18 Lg Life Sciences Ltd composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3219318A4 (en) * 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
CA3002916A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
CA3038557A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
JP3254219B2 (ja) 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
NZ324446A (en) * 1995-12-22 1999-08-30 Kowa Co Pharmaceutical composition containing (e)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropyl-quinolin -3'-yl]-6-heptenoic acid where the aqueous solution or dispersion of the composition has a ph of 7 to less than 8
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
NZ508544A (en) 1998-06-05 2002-10-25 Warner Lambert Co Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2396593A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
CZ298411B6 (cs) 2007-09-26
CZ299105B6 (cs) 2008-04-23
JP4800988B2 (ja) 2011-10-26
AU5184100A (en) 2001-08-02
NZ531474A (en) 2007-04-27
AP1449A (en) 2005-07-28
ITTO20000779A1 (it) 2002-02-04
TW553749B (en) 2003-09-21
HUP0003111A3 (en) 2003-03-28
BR0003364A (pt) 2001-09-18
AR025055A1 (es) 2002-11-06
US6316460B1 (en) 2001-11-13
HRP20080525A2 (en) 2008-12-31
FI20001750A0 (fi) 2000-08-04
HRP20020632A2 (en) 2004-12-31
AU781269C (en) 2006-11-30
CN1149997C (zh) 2004-05-19
NO327675B1 (no) 2009-09-07
AP1879A (en) 2008-08-14
KR100698333B1 (ko) 2007-03-23
IS6480A (is) 2002-07-23
NO327554B1 (no) 2009-08-10
SE0002827L (sv) 2001-07-27
KR20030036492A (ko) 2003-05-09
IS8620A (is) 2007-03-07
BR0003365A (pt) 2001-09-18
SK11782000A3 (sk) 2001-12-03
IS2805B (is) 2012-09-15
SE523481C2 (sv) 2004-04-20
YU5202A (sh) 2004-12-31
CA2639407C (en) 2011-09-13
CA2315141A1 (en) 2001-07-26
AU2000264559A1 (en) 2001-08-07
RU2002122752A (ru) 2004-03-10
NO20003967L (no) 2001-07-27
PL341855A1 (en) 2001-07-30
GB0019028D0 (en) 2000-09-27
HK1040936A1 (en) 2002-06-28
DE10038108A1 (de) 2001-08-02
HK1048950A1 (zh) 2003-04-25
HRP20020097B1 (en) 2010-12-31
GB2358582A (en) 2001-08-01
FR2804025B1 (fr) 2002-08-23
IL187416A0 (en) 2008-02-09
HK1047052A1 (zh) 2003-02-07
AR023624A1 (es) 2002-09-04
HK1040936B (zh) 2010-06-11
NO312434B1 (no) 2002-05-13
DK200001171A (da) 2001-07-27
ITTO20000780A1 (it) 2000-11-04
SE0002826L (sv) 2001-07-27
BG106393A (en) 2002-07-31
ITTO20000779A0 (it) 2000-08-04
CN1319396A (zh) 2001-10-31
BG110353A (en) 2009-09-30
HUP0003111A2 (hu) 2002-02-28
BG66168B1 (bg) 2011-10-31
PT102503A (pt) 2000-12-29
FR2804025A1 (fr) 2001-07-27
AU781269B2 (en) 2005-05-12
AU738074B2 (en) 2001-09-06
CN1282581A (zh) 2001-02-07
FI20105657A (fi) 2010-06-10
DK178242B1 (da) 2015-09-28
HUP0003110A3 (en) 2003-02-28
BG66159B1 (bg) 2011-09-30
MEP33708A (en) 2010-10-10
HK1200368A1 (en) 2015-08-07
TR200201888T2 (tr) 2002-11-21
JP3267960B2 (ja) 2002-03-25
AU5184200A (en) 2001-08-02
EP1223918B1 (en) 2003-02-05
IL147870A0 (en) 2002-08-14
CA2639407A1 (en) 2001-07-26
HK1036934A1 (en) 2002-01-25
HU222578B1 (hu) 2003-08-28
KR20000072135A (ko) 2000-12-05
AR060248A2 (es) 2008-06-04
EP2266540A1 (en) 2010-12-29
FI20001749A (fi) 2001-07-27
CN100528161C (zh) 2009-08-19
ME00191B (me) 2010-10-10
EE05586B1 (et) 2012-10-15
ZA200003997B (en) 2000-08-14
SE0002826D0 (sv) 2000-08-04
NL1015859A1 (nl) 2001-07-27
IS1940B (is) 2004-07-16
PL341853A1 (en) 2001-01-29
EE200200411A (et) 2003-12-15
CL2007001807A1 (es) 2008-01-18
ZA200003998B (en) 2000-08-14
EP2133070A1 (en) 2009-12-16
AU2005202392B2 (en) 2008-11-20
DE10038110A1 (de) 2001-08-23
PT102504A (pt) 2001-07-31
FI111806B (fi) 2003-09-30
GB0001621D0 (en) 2000-03-15
UA51853C2 (uk) 2002-12-16
AU2005202392C1 (en) 2016-06-02
JP2001206847A (ja) 2001-07-31
FI121365B (fi) 2010-10-29
CN101028268A (zh) 2007-09-05
DE60001371D1 (de) 2003-03-13
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
YU52902A (sh) 2006-01-16
NO20003968L (no) 2001-07-27
RU2264210C2 (ru) 2005-11-20
RS50201B (sr) 2009-07-15
HU0003110D0 (en) 2000-10-28
ME00202B (me) 2010-10-10
PT102503B (pt) 2004-02-27
CR6568A (es) 2004-03-05
WO2001054668A1 (en) 2001-08-02
CH700184B1 (de) 2010-07-15
EE05221B1 (et) 2009-10-15
HU0003111D0 (en) 2000-10-28
TR200701171T2 (tr) 2007-04-24
FI20001749A0 (fi) 2000-08-04
EE04990B1 (et) 2008-04-15
FI20001750A (fi) 2001-07-27
ATE232088T1 (de) 2003-02-15
EP2018853A1 (en) 2009-01-28
EE200200052A (et) 2003-04-15
CR10114A (es) 2008-08-21
US6548513B1 (en) 2003-04-15
FR2795324B1 (fr) 2002-05-17
EP1223918A1 (en) 2002-07-24
AP2002002409A0 (en) 2002-03-31
TWI228050B (en) 2005-02-21
EP1251831A1 (en) 2002-10-30
IL150513A (en) 2012-12-31
HRP20020632B1 (en) 2010-12-31
EE200900047A (et) 2011-04-15
HUP0003110A2 (hu) 2001-05-28
CA2315141C (en) 2009-08-18
CZ20002884A3 (cs) 2001-09-12
CZ290167B6 (cs) 2002-06-12
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
BE1013414A5 (fr) 2001-12-04
ATA13602000A (de) 2004-02-15
SE523471C2 (sv) 2004-04-20
NL1015859C2 (nl) 2001-10-16
NO2010005I1 (no) 2010-05-03
SE0002827D0 (sv) 2000-08-04
DE10038110B4 (de) 2006-06-29
JP2007182452A (ja) 2007-07-19
CR6687A (es) 2005-07-18
NO20003967D0 (no) 2000-08-04
IS6254A (is) 2002-01-29
GB0019029D0 (en) 2000-09-27
KR20010077840A (ko) 2001-08-20
HK1036935A1 (en) 2002-01-25
MY123650A (en) 2006-05-31
AU2005202392A1 (en) 2005-06-30
SK283872B6 (sk) 2004-03-02
CZ20002883A3 (cs) 2000-10-11
ES2171123A1 (es) 2002-08-16
IL150513A0 (en) 2003-02-12
JP2001206877A (ja) 2001-07-31
BG106926A (bg) 2003-04-30
CA2313783C (en) 2002-03-12
AT412063B (de) 2004-09-27
UA77156C2 (en) 2006-11-15
ES2171123B1 (es) 2003-11-16
AT412062B (de) 2004-09-27
EP2774609A1 (en) 2014-09-10
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
NZ519774A (en) 2004-04-30
GB2358583B (en) 2002-02-06
DK1223918T3 (da) 2003-04-28
WO2001054669A1 (en) 2001-08-02
NO20071303L (no) 2001-07-27
BE1013413A3 (fr) 2001-12-04
DK200001170A (da) 2001-01-27
AP2002002591A0 (en) 2002-09-30
PL196808B1 (pl) 2008-02-29
GB2358582B (en) 2004-09-29
PT1223918E (pt) 2003-06-30
IL147870A (en) 2003-10-31
FR2795324A1 (fr) 2000-12-29
TR200200270T2 (tr) 2002-06-21
DE60001371T2 (de) 2004-01-22
CA2313783A1 (en) 2000-10-16
BG65234B1 (bg) 2007-09-28
KR100388713B1 (ko) 2003-06-25
AU6580000A (en) 2001-08-07
CH691347A5 (de) 2001-07-13
ES2155043B1 (es) 2001-12-01
SI1223918T1 (en) 2003-06-30
NL1015858C2 (nl) 2001-07-27
SK11792000A3 (sk) 2001-12-03
MY122707A (en) 2006-04-29
JP4800467B2 (ja) 2011-10-26
ATA13612000A (de) 2004-02-15

Similar Documents

Publication Publication Date Title
NO20003967D0 (no) Farmasøytiske preparater
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
DE50100710D1 (de) Wischblatt
NO20030276D0 (no) Fremgangsmåte
ATE298751T1 (de) 7-oxopyridoryrimidine
ATE262530T1 (de) Indolochinazolinone
DE1274523T1 (de) Hochdruckumformspülanlage
DE10192638T1 (de) Bohrstangenladevorrichtung
DK1331972T3 (da) Farmaceutiske præparater
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50011511D1 (de) Blowby-Heizung
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ATE476423T1 (de) Benzoylpyridazine
DE50007634D1 (de) Kardioplegieballonkatheter
DE10052925B4 (de) Schaukelbett
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE10195909T1 (de) Viehfüttervorrichtung
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone

Legal Events

Date Code Title Description
MK1K Patent expired